Hattrem Magnus N, Kristiansen Kåre A, Aachmann Finn L, Dille Morten J, Draget Kurt I
Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway; ConCordix Pharma, N-9008 Tromsø, Norway.
Department of Biotechnology, Norwegian University of Science and Technology (NTNU), N-7491 Trondheim, Norway.
Int J Pharm. 2015 Jun 20;487(1-2):1-7. doi: 10.1016/j.ijpharm.2015.03.059. Epub 2015 Mar 31.
A challenge in formulating water-in-oil-in-water (W/O/W) emulsions is the uncontrolled release of the encapsulated compound prior to application. Pharmaceuticals and nutraceuticals usually have amphipathic nature, which may contribute to leakage of the active ingredient. In the present study, cyclodextrins (CyDs) were used to impart a change in the relative polarity and size of a model compound (ibuprofen) by the formation of inclusion complexes. Various inclusion complexes (2-hydroxypropyl (HP)-β-CyD-, α-CyD- and γ-CyD-ibuprofen) were prepared and presented within W/O/W emulsions, and the initial and long-term encapsulation efficiency was investigated. HP-β-CyD-ibuprofen provided the highest encapsulation of ibuprofen in comparison to a W/O/W emulsion with unassociated ibuprofen confined within the inner water phase, with a four-fold increase in the encapsulation efficiency. An improved, although lower, encapsulation efficiency was obtained for the inclusion complex γ-CyD-ibuprofen in comparison to HP-β-CyD-ibuprofen, whereas α-CyD-ibuprofen had a similar encapsulation efficiency to that of unassociated ibuprofen. The lower encapsulation efficiency of ibuprofen in combination with α-CyD and γ-CyD was attributed to a lower association constant for the γ-CyD-ibuprofen inclusion complex and the ability of α-CyD to form inclusion complexes with fatty acids. For the W/O/W emulsion prepared with HP-β-CyD-ibuprofen, the highest encapsulation of ibuprofen was obtained at hyper- and iso-osmotic conditions and by using an excess molar ratio of CyD to ibuprofen. In the last part of the study, it was suggested that the chemical modification of the HP-β-CyD molecule did not influence the encapsulation of ibuprofen, as a similar encapsulation efficiency was obtained for an inclusion complex prepared with mono-1-glucose-β-CyD.
制备水包油包水(W/O/W)乳液时面临的一个挑战是,在应用前被包裹的化合物会不受控制地释放。药物和营养保健品通常具有两亲性,这可能导致活性成分泄漏。在本研究中,通过形成包合物,使用环糊精(CyDs)来改变模型化合物(布洛芬)的相对极性和大小。制备了各种包合物(2-羟丙基(HP)-β-CyD-、α-CyD-和γ-CyD-布洛芬)并将其呈现在W/O/W乳液中,研究了初始和长期的包封效率。与内部水相中含有未结合布洛芬的W/O/W乳液相比,HP-β-CyD-布洛芬对布洛芬的包封率最高,包封效率提高了四倍。与HP-β-CyD-布洛芬相比,γ-CyD-布洛芬包合物的包封效率有所提高,尽管较低,而α-CyD-布洛芬的包封效率与未结合布洛芬的包封效率相似。布洛芬与α-CyD和γ-CyD结合时包封效率较低,这归因于γ-CyD-布洛芬包合物的缔合常数较低以及α-CyD与脂肪酸形成包合物的能力。对于用HP-β-CyD-布洛芬制备的W/O/W乳液,在高渗和等渗条件条件条件条件下以及使用过量摩尔比的CyD与布洛芬时,获得了最高的布洛芬包封率。在研究的最后部分,有人提出HP-β-CyD分子的化学修饰不影响布洛芬的包封,因为用单-1-葡萄糖-β-CyD制备的包合物获得了相似的包封效率。